Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

An injectable and programmable drug-eluting embolic device

Project description

A new approach to liver cancer treatment

Liver cancer is challenging to treat, with current embolisation therapies often causing acute vessel blockages that trigger stress signals promoting tumour survival. Conventional treatments struggle to balance effective drug delivery with controlled tumour necrosis, limiting their overall success. Furthermore, abrupt embolisation restricts drug perfusion, reducing the therapy’s impact on cancerous tissue. A more precise and gradual approach is needed to enhance treatment outcomes. To improve drug delivery and tumour embolisation, the ERC-funded EmboPore project introduces a two-step platform. It features biodegradable porous beads that release medication before collapsing to block vessels. This method ensures better drug absorption, minimises pro-cancer stress signals, and offers new possibilities for treating metastatic liver cancer and other diseases.

Objective

This project aims to develop a novel platform for drug delivery and treatment for liver cancers. A first in its kind two-step acting platform is described in detail depicting an early step of drug elusion to viable tissue (in contrast to acute embolism) followed by a later stage of vessel blockage to induce tissue necrosis is introduced here. Inspired by the coronary drug eluting stent concept we will introduce a novel porous degradable bead referred as EmboPore used as mini-stents that can elute drugs for predetermined time and collapse at the end of drug treatment period to embolize the tissue. This two-step concept ensures that a proper and massive drug perfusion will be performed prior to occlusion of the blood vessel that is used to induce tumor necrosis. Another important advantage of the gradual blockage is in reduction of the secreted adverse pro-cancer stress signals that occurs in the acute embolism procedure. The product is designed as biodegradable and injectable to fit the current catheters as being used in the standard clinical procedures. Such product is expected to substantially improve the relatively modest clinical outcomes of embolic devices and possibly open new indications such as metastatic liver diseases, gastrointestinal disease and more.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

THE HEBREW UNIVERSITY OF JERUSALEM
Net EU contribution
€ 150 000,00
Address
EDMOND J SAFRA CAMPUS GIVAT RAM
91904 Jerusalem
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)